Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C10H20N2S4 |
| Molecular Weight | 296.539 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCN(CC)C(=S)SSC(=S)N(CC)CC
InChI
InChIKey=AUZONCFQVSMFAP-UHFFFAOYSA-N
InChI=1S/C10H20N2S4/c1-5-11(6-2)9(13)15-16-10(14)12(7-3)8-4/h5-8H2,1-4H3
| Molecular Formula | C10H20N2S4 |
| Molecular Weight | 296.539 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionSources: http://www.drugbank.ca/drugs/DB00822Curator's Comment: Description was created based on several sources, including
https://www.drugs.com/pro/disulfiram.html
Sources: http://www.drugbank.ca/drugs/DB00822
Curator's Comment: Description was created based on several sources, including
https://www.drugs.com/pro/disulfiram.html
Disulfiram is a carbamate derivative used as an alcohol deterrent. It is a relatively nontoxic substance when administered alone, but markedly alters the intermediary metabolism of alcohol. Disulfiram blocks the oxidation of alcohol at the acetaldehyde stage during alcohol metabolism following disulfiram intake causing an accumulation of acetaldehyde in the blood producing highly unpleasant symptoms. Disulfiram blocks the oxidation of alcohol through its irreversible inactivation of aldehyde dehydrogenase, which acts in the second step of ethanol utilization. In addition, disulfiram competitively binds and inhibits the peripheral benzodiazepine receptor, which may indicate some value in the treatment of the symptoms of alcohol withdrawal, however this activity has not been extensively studied. Used for the treatment and management of chronic alcoholism.
CNS Activity
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL1935 Sources: http://www.drugbank.ca/drugs/DB00822 |
|||
Target ID: CHEMBL5101 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19664055 |
3.3 µM [IC50] | ||
Target ID: CHEMBL3577 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19296407 |
101.0 µM [IC50] | ||
Target ID: GO:0097251 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1647348 |
4.6 µM [IC50] | ||
Target ID: CHEMBL3102 Sources: http://www.drugbank.ca/drugs/DB00822 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Disulfiram Approved UseDisulfiram is an aid in the management of selected chronic alcohol patients who want to remain in a state of enforced sobriety so that supportive and psychotherapeutic treatment may be applied to best advantage. Launch Date1981 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1.3 nM EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/1471547 |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
DISULFIRAM plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
54.696 ng/mL |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
DISULFIRAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
715.144 ng × h/mL |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
DISULFIRAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
7.3 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/1471547 |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
DISULFIRAM plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
9.82 h |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
DISULFIRAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
OverviewOther
| Other Inhibitor | Other Substrate | Other Inducer |
|---|---|---|
Drug as perpetrator
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| no | no (co-administration study) Comment: Results show that single-dose disulfiram does not cause clinically significant inhibition of human CYP2C9, 2C19, 2D6, and 3A4 activities in vivo Sources: https://pubmed.ncbi.nlm.nih.gov/10348802/ |
|||
| no | no (co-administration study) Comment: Results show that single-dose disulfiram does not cause clinically significant inhibition of human CYP2C9, 2C19, 2D6, and 3A4 activities in vivo Sources: https://pubmed.ncbi.nlm.nih.gov/10348802/ |
|||
| no | no (co-administration study) Comment: Results show that single-dose disulfiram does not cause clinically significant inhibition of human CYP2C9, 2C19, 2D6, and 3A4 activities in vivo Sources: https://pubmed.ncbi.nlm.nih.gov/10348802/ |
|||
| no | no (co-administration study) Comment: Results show that single-dose disulfiram does not cause clinically significant inhibition of human CYP2C9, 2C19, 2D6, and 3A4 activities in vivo Sources: https://pubmed.ncbi.nlm.nih.gov/10348802/ |
|||
| yes [Ki 12.1 uM] | ||||
| yes | yes (co-administration study) Comment: Disulfiram, a selective inhibitor of human hepatic P450 2E1, prevented 80-90% of isoflurane metabolism |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Manic episode with psychosis following a lower than recommended dosage regimen of disulfiram. | 2008-01-01 |
|
| Behavioral couples therapy for comorbid substance use disorders and combat-related posttraumatic stress disorder among male veterans: an initial evaluation. | 2008-01 |
|
| Adverse effects of excessive nitric oxide on cytochrome c oxidase in lenses of hereditary cataract UPL rats. | 2007-12-05 |
|
| Disulfiram-induced transient optic and peripheral neuropathy: a case report. | 2007-12 |
|
| Quantity of ethanol absorption after excessive hand disinfection using three commercially available hand rubs is minimal and below toxic levels for humans. | 2007-10-11 |
|
| [Acute encephalopathy secondary to treatment with disulfiram]. | 2007-10-06 |
|
| Perturbation of retinoic acid (RA)-mediated limb development suggests a role for diminished RA signaling in the teratogenesis of ethanol. | 2007-09 |
|
| Hypotension and ST depression as a result of disulfiram ethanol reaction. | 2007-08 |
|
| Disulfiram is an inhibitor of human purified monoacylglycerol lipase, the enzyme regulating 2-arachidonoylglycerol signaling. | 2007-07-23 |
|
| Induction of tibial dyschondroplasia by carbamate and thiocarbamate pesticides. | 2007-06 |
|
| Manic episode with psychotic symptoms associated with high dose of disulfiram: a case report. | 2007-04 |
|
| Naltrexone and disulfiram in patients with alcohol dependence and current depression. | 2007-04 |
|
| Disulfiram effects on responses to intravenous cocaine administration. | 2007-03-16 |
|
| Pharmacological profiling of disulfiram using human tumor cell lines and human tumor cells from patients. | 2007-01-01 |
|
| Refractive hypotension in a patient with disulfiram-ethanol reaction. | 2007-01 |
|
| Bench-to-bedside review: current evidence for extracorporeal albumin dialysis systems in liver failure. | 2007 |
|
| [Disulfiram-induced delirium: a case report]. | 2006-12 |
|
| Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity. | 2006-11-01 |
|
| Antabuse reaction with ceftin. | 2006-11 |
|
| [Optic neuropathy while taking disulfiram]. | 2006-10 |
|
| Choosing the right medication for the treatment of alcoholism. | 2006-10 |
|
| Involvement of drug-specific T cells in acute drug-induced interstitial nephritis. | 2006-10 |
|
| The catatonic dilemma expanded. | 2006-09-07 |
|
| [New developments in the pharmacotherapy of cocaine dependence]. | 2006-09 |
|
| Quantification of breath carbon disulphide and acetone following a single dose of disulfiram (Antabuse) using selected ion flow tube mass spectrometry (SIFT-MS). | 2006-06 |
|
| [Is Antabus therapy connected with reduced efficacy of nitroglycerin?]. | 2006-04-24 |
|
| Transgenic analysis of the medaka mesp-b enhancer in somitogenesis. | 2006-04 |
|
| Clinical characteristics and prognostic markers in disulfiram-induced liver injury. | 2006-04 |
|
| Disulfiram irreversibly aggregates betaine aldehyde dehydrogenase--a potential target for antimicrobial agents against Pseudomonas aeruginosa. | 2006-03-10 |
|
| Cross-reactivity between thiurams. | 2006-03 |
|
| Effects of dopamine beta-hydroxylase genotype and disulfiram inhibition on catecholamine homeostasis in mice. | 2005-11 |
|
| [The first to go--physicians who experimented on themselves]. | 2005-09-08 |
|
| Fulminant drug-induced hepatic failure leading to death or liver transplantation in Sweden. | 2005-09 |
|
| Effect of inducers of DT-diaphorase on the haemolytic activity and nephrotoxicity of 2-amino-1,4-naphthoquinone in rats. | 2005-08-15 |
|
| Disulfiram metabolites permanently inactivate the human multidrug resistance P-glycoprotein. | 2005-07-21 |
|
| Are alcoholism treatments effective? The Project MATCH data. | 2005-07-14 |
|
| Pharmacokinetics, safety, and tolerability of a depot formulation of naltrexone in alcoholics: an open-label trial. | 2005-04-01 |
|
| Acute liver failure: a message found under the skin. | 2005-04 |
|
| Cutaneous metabolism of glycol ethers. | 2005-03 |
|
| Resistance of zwitterionic telomers accumulated on metal surfaces against nonspecific adsorption of proteins. | 2005-02-15 |
|
| Clioquinol and pyrrolidine dithiocarbamate complex with copper to form proteasome inhibitors and apoptosis inducers in human breast cancer cells. | 2005 |
|
| [Anterior myocardial infarction in a chronic alcoholic man on disulfiram therapy: a case report]. | 2004-12 |
|
| One-pot synthesis of high-quality zinc-blende CdS nanocrystals. | 2004-11-10 |
|
| Preparation of mononuclear and dinuclear Rh hydrotris(pyrazolyl)borato complexes containing arenethiolato ligands and conversion of the mononuclear complexes into dinuclear Rh-Rh and Rh-Ir complexes with bridging arenethiolato ligands. | 2004-11-07 |
|
| Ask the doctor. I need to quit drinking, but don't think I can do it on my own. Can I use a drug like Antabuse even though I have heart disease? | 2004-10 |
|
| Disulfiram is a potent modulator of multidrug transporter Cdr1p of Candida albicans. | 2004-09-17 |
|
| Disulfiram inhibits activating transcription factor/cyclic AMP-responsive element binding protein and human melanoma growth in a metal-dependent manner in vitro, in mice and in a patient with metastatic disease. | 2004-09 |
|
| Disulfiram-induced fulminant hepatic failure in an active duty soldier. | 2004-08 |
|
| Effectiveness of some means using against root rot on parsley seedling root. | 2004 |
|
| Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects. | 1991-03-01 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/dosage/disulfiram.html
Usual Adult Dose for Alcohol Dependence
-Initial dose: 500 mg orally once a day (this dose is generally continued for the first 1 to 2 weeks)
-Maintenance dose: 250 mg orally once a day (range: 125 mg to 500 mg once a day)
Maximum dose: 500 mg once a day
-Duration of therapy: Depending on the individual, therapy may last months or even years
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25984987
Application of 1mM disulfiram to R. jostii RHA1, gave rise to 4-carboxymuconolactone on the β-ketoadipate pathway
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:35:03 GMT 2025
by
admin
on
Mon Mar 31 17:35:03 GMT 2025
|
| Record UNII |
TR3MLJ1UAI
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-VATC |
QN07BB01
Created by
admin on Mon Mar 31 17:35:03 GMT 2025 , Edited by admin on Mon Mar 31 17:35:03 GMT 2025
|
||
|
WHO-ATC |
P03AA04
Created by
admin on Mon Mar 31 17:35:03 GMT 2025 , Edited by admin on Mon Mar 31 17:35:03 GMT 2025
|
||
|
FDA ORPHAN DRUG |
522516
Created by
admin on Mon Mar 31 17:35:03 GMT 2025 , Edited by admin on Mon Mar 31 17:35:03 GMT 2025
|
||
|
WHO-ATC |
N07BB01
Created by
admin on Mon Mar 31 17:35:03 GMT 2025 , Edited by admin on Mon Mar 31 17:35:03 GMT 2025
|
||
|
NCI_THESAURUS |
C2160
Created by
admin on Mon Mar 31 17:35:03 GMT 2025 , Edited by admin on Mon Mar 31 17:35:03 GMT 2025
|
||
|
LIVERTOX |
NBK548103
Created by
admin on Mon Mar 31 17:35:03 GMT 2025 , Edited by admin on Mon Mar 31 17:35:03 GMT 2025
|
||
|
NDF-RT |
N0000175679
Created by
admin on Mon Mar 31 17:35:03 GMT 2025 , Edited by admin on Mon Mar 31 17:35:03 GMT 2025
|
||
|
NCI_THESAURUS |
C1744
Created by
admin on Mon Mar 31 17:35:03 GMT 2025 , Edited by admin on Mon Mar 31 17:35:03 GMT 2025
|
||
|
WHO-ATC |
P03AA54
Created by
admin on Mon Mar 31 17:35:03 GMT 2025 , Edited by admin on Mon Mar 31 17:35:03 GMT 2025
|
||
|
NDF-RT |
N0000000183
Created by
admin on Mon Mar 31 17:35:03 GMT 2025 , Edited by admin on Mon Mar 31 17:35:03 GMT 2025
|
||
|
FDA ORPHAN DRUG |
771520
Created by
admin on Mon Mar 31 17:35:03 GMT 2025 , Edited by admin on Mon Mar 31 17:35:03 GMT 2025
|
||
|
NCI_THESAURUS |
C1742
Created by
admin on Mon Mar 31 17:35:03 GMT 2025 , Edited by admin on Mon Mar 31 17:35:03 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
202-607-8
Created by
admin on Mon Mar 31 17:35:03 GMT 2025 , Edited by admin on Mon Mar 31 17:35:03 GMT 2025
|
PRIMARY | |||
|
CHEMBL964
Created by
admin on Mon Mar 31 17:35:03 GMT 2025 , Edited by admin on Mon Mar 31 17:35:03 GMT 2025
|
PRIMARY | |||
|
97-77-8
Created by
admin on Mon Mar 31 17:35:03 GMT 2025 , Edited by admin on Mon Mar 31 17:35:03 GMT 2025
|
PRIMARY | |||
|
DB00822
Created by
admin on Mon Mar 31 17:35:03 GMT 2025 , Edited by admin on Mon Mar 31 17:35:03 GMT 2025
|
PRIMARY | |||
|
1224008
Created by
admin on Mon Mar 31 17:35:03 GMT 2025 , Edited by admin on Mon Mar 31 17:35:03 GMT 2025
|
PRIMARY | |||
|
TR3MLJ1UAI
Created by
admin on Mon Mar 31 17:35:03 GMT 2025 , Edited by admin on Mon Mar 31 17:35:03 GMT 2025
|
PRIMARY | |||
|
m4677
Created by
admin on Mon Mar 31 17:35:03 GMT 2025 , Edited by admin on Mon Mar 31 17:35:03 GMT 2025
|
PRIMARY | Merck Index | ||
|
7168
Created by
admin on Mon Mar 31 17:35:03 GMT 2025 , Edited by admin on Mon Mar 31 17:35:03 GMT 2025
|
PRIMARY | |||
|
DISULFIRAM
Created by
admin on Mon Mar 31 17:35:03 GMT 2025 , Edited by admin on Mon Mar 31 17:35:03 GMT 2025
|
PRIMARY | |||
|
1781
Created by
admin on Mon Mar 31 17:35:03 GMT 2025 , Edited by admin on Mon Mar 31 17:35:03 GMT 2025
|
PRIMARY | |||
|
928
Created by
admin on Mon Mar 31 17:35:03 GMT 2025 , Edited by admin on Mon Mar 31 17:35:03 GMT 2025
|
PRIMARY | |||
|
3554
Created by
admin on Mon Mar 31 17:35:03 GMT 2025 , Edited by admin on Mon Mar 31 17:35:03 GMT 2025
|
PRIMARY | RxNorm | ||
|
SUB06326MIG
Created by
admin on Mon Mar 31 17:35:03 GMT 2025 , Edited by admin on Mon Mar 31 17:35:03 GMT 2025
|
PRIMARY | |||
|
4659
Created by
admin on Mon Mar 31 17:35:03 GMT 2025 , Edited by admin on Mon Mar 31 17:35:03 GMT 2025
|
PRIMARY | |||
|
C447
Created by
admin on Mon Mar 31 17:35:03 GMT 2025 , Edited by admin on Mon Mar 31 17:35:03 GMT 2025
|
PRIMARY | |||
|
DTXSID1021322
Created by
admin on Mon Mar 31 17:35:03 GMT 2025 , Edited by admin on Mon Mar 31 17:35:03 GMT 2025
|
PRIMARY | |||
|
25953
Created by
admin on Mon Mar 31 17:35:03 GMT 2025 , Edited by admin on Mon Mar 31 17:35:03 GMT 2025
|
PRIMARY | |||
|
D004221
Created by
admin on Mon Mar 31 17:35:03 GMT 2025 , Edited by admin on Mon Mar 31 17:35:03 GMT 2025
|
PRIMARY | |||
|
TR3MLJ1UAI
Created by
admin on Mon Mar 31 17:35:03 GMT 2025 , Edited by admin on Mon Mar 31 17:35:03 GMT 2025
|
PRIMARY | |||
|
disulfiram
Created by
admin on Mon Mar 31 17:35:03 GMT 2025 , Edited by admin on Mon Mar 31 17:35:03 GMT 2025
|
PRIMARY | |||
|
3117
Created by
admin on Mon Mar 31 17:35:03 GMT 2025 , Edited by admin on Mon Mar 31 17:35:03 GMT 2025
|
PRIMARY | |||
|
3317
Created by
admin on Mon Mar 31 17:35:03 GMT 2025 , Edited by admin on Mon Mar 31 17:35:03 GMT 2025
|
PRIMARY | |||
|
100000081855
Created by
admin on Mon Mar 31 17:35:03 GMT 2025 , Edited by admin on Mon Mar 31 17:35:03 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
METABOLITE ACTIVE -> PRODRUG |
|
||
|
METABOLITE -> PARENT | |||
|
METABOLITE -> PARENT |
|
||
|
METABOLITE -> PARENT |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
|